Direkt zum Inhalt

Pavel, Vlad ; Mester, Patricia ; Schmid, Stephan ; Krautbauer, Sabrina ; Höring, Marcus ; Liebisch, Gerhard ; Müller, Martina ; Buechler, Christa

Hexosylceramide Species in the Blood Decline in Both COVID-19 and Non-COVID-19 Sepsis

Artikel

Pavel, Vlad , Mester, Patricia , Schmid, Stephan , Krautbauer, Sabrina, Höring, Marcus , Liebisch, Gerhard , Müller, Martina und Buechler, Christa (2026) Hexosylceramide Species in the Blood Decline in Both COVID-19 and Non-COVID-19 Sepsis. Biomedicines 14 (7), S. 1635.

DOI zum Zitieren dieses Dokuments: 10.5283/epub.80809


Zusammenfassung

Background/Objectives: Hexosylceramides (HexCers) are bioactive lipids whose circulating levels have been associated with severe illness. Blood lipid profiles differ between COVID-19 and non-COVID-19 sepsis and are also affected by liver cirrhosis. To evaluate the impact of SARS-CoV-2 infection and investigate associations with disease severity and underlying liver cirrhosis among circulating ...

Background/Objectives: Hexosylceramides (HexCers) are bioactive lipids whose circulating levels have been associated with severe illness. Blood lipid profiles differ between COVID-19 and non-COVID-19 sepsis and are also affected by liver cirrhosis. To evaluate the impact of SARS-CoV-2 infection and investigate associations with disease severity and underlying liver cirrhosis among circulating HexCer species, we analyzed plasma samples from patients with systemic inflammatory response syndrome (SIRS), sepsis, or septic shock. Methods: Plasma levels of five HexCer species were quantified by flow injection analysis tandem mass spectrometry (FIA-MS/MS) in 159 patients with SIRS, sepsis, or septic shock. Among these patients, 24 had COVID-19, and 31 liver cirrhosis. In addition, serum HexCer levels were analyzed in 41 patients with moderate and 61 patients with severe COVID-19. Results: Patients with SIRS, sepsis or septic shock exhibited largely comparable plasma HexCer18:1;O2/22:0, 23:0, and 24:0 concentrations, all of which were significantly lower than those observed in healthy controls. These species and in addition HexCer18:1;O2/16:0 and 24:1 levels were modestly lower in patients with septic shock compared to those with SIRS. No significant differences in any of the five HexCer species were observed between patients with COVID-19 and non-COVID-19 septic shock or between ventilated patients with and without COVID-19, indicating that circulating HexCer levels are associated with disease severity rather than SARS-CoV-2 infection. HexCer18:1;O2/24:1 levels were increased in patients with cirrhosis. No significant differences in HexCer levels were observed between survivors and non-survivors. Conclusions: In COVID-19 and non-COVID-19 patients circulating levels of HexCer18:1;O2/22:0, HexCer18:1;O2/23:0, and HexCer18:1;O2/24:0 decline early during systemic inflammation, whereas reductions in HexCer18:1;O2/16:0 and 24:1 levels become apparent in septic shock. These findings indicate that alterations in circulating HexCer species reflect sepsis severity rather than being specific to COVID-19.



Beteiligte Einrichtungen


Details

DokumentenartArtikel
Titel eines Journals oder einer ZeitschriftBiomedicines
VerlagMDPI
Open Access ArtGold (mit APC - bezahlt UR)
Band14
Nummer des Zeitschriftenheftes oder des Kapitels7
SeitenbereichS. 1635
Datum20 Juli 2026
Veröffentlichungsdatum25 Sep 2026 08:40
InstitutionenMedizin > Lehrstuhl für Innere Medizin I
Identifikationsnummer
WertTyp
10.3390/biomedicines14071635DOI
Stichwörter / Keywordsliver cirrhosis; hexosylceramide; sepsis; ventilation
Dewey-Dezimal-Klassifikation600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin
StatusVeröffentlicht
BegutachtetJa, diese Version wurde begutachtet
An der Universität Regensburg entstandenJa
URN der UB Regensburgurn:nbn:de:bvb:355-epub-808098
Dokumenten-ID80809

Bibliographische Daten exportieren

Nur für Besitzer und Autoren: Kontrollseite des Eintrags

nach oben